Eliot L. Siegel MD, Presenter: Research Grant, General Electric Company Speakers Bureau, Siemens AG Board of Directors, Carestream Health, Inc Research Grant, XYBIX Systems, Inc Research Grant, Steelcase, Inc Research Grant, Anthro Corp Research Grant, RedRick Technologies Inc Research Grant, Evolved Technologies Corporation Research Grant, Barco nv Research Grant, Intel Corporation Research Grant, Dell Inc Research Grant, Herman Miller, Inc Research Grant, Virtual Radiology Research Grant, Anatomical Travelogue, Inc Medical Advisory Board, Fovia, Inc Medical Advisory Board, Toshiba Corporation Medical Advisory Board, McKesson Corporation Medical Advisory Board, Carestream Health, Inc Medical Advisory Board, Bayer AG Research, TeraRecon, Inc Medical Advisory Board, Bracco Group Researcher, Bracco Group Medical Advisory Board, Merge Healthcare Incorporated Medical Advisory Board, Microsoft Corporation Researcher, Microsoft Corporation

1) Describe how data from a clinical trial can be repurposed as a decision support tool. 2) List some of the potential techniques that can be utilized to predict likelihood of a malignant nodule from the NLST database. 3) Explain how the Fleischner Guidelines can be personalized utilizing data from NLST and PLCO. 4) Detail the implications for lung screening trials of having access to NLST and PLCO data. 5) Demonstrate how a healthcare enterprise can create their own local reference database using information from their own patient population.

The era of personalized/precision medicine offers the potential to utilize patient and lesion specific data to personalize screening and diagnostic work-up, diagnosis, and treatment selection to a particular patient to optimize effectiveness. Although recently, the emphasis has been on utilization of genomic data in personalized medicine, there is a "gold mine" of useful data in previously conducted clinical trials as well as patient medical electronic records that has, until now, gone largely untapped.  The purpose of this presentation is to describe how the screening, diagnosis, and treatment of lung nodules can be personalized utilizing data from the NLST and PLCO clinical trials and how the Fleischner Guidelines and screening criteria for lung cancer can be modified according to the characteristics of an individual patient and individual nodule.  The presentation will also include ways in which a facility can collect local data on their own patients to supplement these reference databases with experience from their own patient population.

Siegel, E, Lung Nodules: Combining Population and Patient Specific Data to Inform Personalized Decision Making.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14001875.html